FY2029 Earnings Estimate for ACRV Issued By HC Wainwright

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Analysts at HC Wainwright issued their FY2029 EPS estimates for Acrivon Therapeutics in a research note issued on Wednesday, March 26th. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of ($1.25) for the year. HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share.

ACRV has been the topic of several other research reports. KeyCorp assumed coverage on shares of Acrivon Therapeutics in a research report on Friday, January 31st. They issued an “overweight” rating on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Acrivon Therapeutics in a report on Wednesday. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $23.17.

Acrivon Therapeutics Stock Performance

Shares of ACRV stock opened at $2.52 on Thursday. Acrivon Therapeutics has a 52-week low of $2.44 and a 52-week high of $11.90. The company has a 50-day simple moving average of $5.42 and a two-hundred day simple moving average of $6.57. The company has a market capitalization of $78.46 million, a price-to-earnings ratio of -0.93 and a beta of 0.85.

Acrivon Therapeutics (NASDAQ:ACRV) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.06.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ACRV. Acorn Capital Advisors LLC bought a new position in Acrivon Therapeutics during the 4th quarter valued at approximately $2,440,000. Exome Asset Management LLC purchased a new stake in shares of Acrivon Therapeutics in the third quarter worth $817,000. State Street Corp increased its holdings in shares of Acrivon Therapeutics by 26.4% during the third quarter. State Street Corp now owns 225,896 shares of the company’s stock valued at $1,581,000 after acquiring an additional 47,233 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Acrivon Therapeutics by 548.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock worth $238,000 after purchasing an additional 28,748 shares during the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Acrivon Therapeutics by 29.7% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,784 shares of the company’s stock worth $619,000 after purchasing an additional 23,535 shares in the last quarter. 71.62% of the stock is owned by hedge funds and other institutional investors.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.